Cerchietti Research Lab

Publications

Found 78 results

Filters: First Letter Of Last Name is R [Clear All Filters]

2021

Marullo R, Castro M, Yomtoubian S, M Calvo-Vidal N, Revuelta MVictoria, Krumsiek J, Cho A, Morgado PCresta, Yang SN, Medina V et al.. 2021. The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases.. Sci Adv. 7(45):eabg1964.

M Calvo-Vidal N, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J et al.. 2021. Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.. Cancer Res. 81(20):5202-5216.

2020

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E et al.. 2020. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.. Cell Rep. 30(3):755-770.e6.

Fiore D, Cappelli LVincenzo, Zumbo P, Phillips JM, Liu Z, Cheng S, Yoffe L, Ghione P, Di Maggio F, Dogan A et al.. 2020. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries.. Cancers (Basel). 12(6)

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

2018

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. 2018. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^.. Leuk Lymphoma. 59(1):256-258.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al.. 2018. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al.. 2018. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al.. 2018. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al.. 2018. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.

Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Roman L, Mann KK, Cerchietti L. 2018. Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.. EBioMedicine. 28:80-89.

2017

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al.. 2017. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov.

Deb D, Rajaram S, Larsen JE, Dospoy PP, Marullo R, Li L-S, Avila K, Cerchietti L, Xue F, Minna J et al.. 2017. Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers.. Cancer Res.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L. 2017. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al.. 2017. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al.. 2017. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al.. 2017. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

2016

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al.. 2016. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al.. 2016. The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al.. 2016. The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al.. 2016. The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al.. 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al.. 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Marullo R, Rutherford SC, Leonard JP, Cerchietti L. 2016. Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.. Cell Cycle. 15(17):2241-7.

2015

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al.. 2015. Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.